投资者是资本市场发展的根基。保护投资者特别是中小投资者的合法权益，是资本市场一切工作的出发 点和落脚点。业内人士表示，当前，我国多层次资本市场改革发展正不断深化，法治化、市场化进程持 续推进。展望未来，随着监管效能的持续提升和司法保障的日益强化，安全、规范、透明、开放、有活 力、有韧性的资本市场必将更好服务实体经济高质量发展，也让每一位投资者都能更安心分享上市公司 发展成果。 二审裁定生效后，执行法院快速将冻结资金发还生物谷，把判决书上的"白纸黑字"迅速转化为上市公司 账上的"真金白银"，对于协助生物谷惩首恶、追损失具有重要意义。目前，生物谷经营状况正常，并对 林艳和及相关主体提起民事诉讼，已被相关法院受理。资金占用案件带来的影响正在逐渐消除。 北交所上市公司生物谷近日公告称，公司资金占用案追款工作取得进展，被冻结在案的款项已全额发还 上市公司账户。从执行程序启动到资金划转至上市公司，全程历时不足一个月。 非经营性占用上市公司资金是严重损害上市公司利益和股东权益的违法行为。2021年8月至2022年3月， 生物谷创始人、前实际控制人林艳和安排时任公司董事会秘书兼财务总监贺元违反财务制度非经营性占 用生物谷资金 ...

投资者是资本市场发展的根基。保护投资者特别是中小投资者的合法权益，是资本市场一切工作的出发 点和落脚点。当前，我国多层次资本市场改革发展正不断深化，市场化、法治化、国际化进程持续推 进。展望未来，随着监管效能的持续提升和司法保障的日益强化，安全、规范、透明、开放、有活力、 有韧性的资本市场必将更好地服务于实体经济高质量发展，也让每一位投资者都能更安心地分享上市公 司发展成果。 （文章来源：证券日报） 本报讯 2月6日晚间，北交所上市公司云南生物谷药业股份有限公司（以下简称"生物谷"）发布公告 称，资金占用案追款工作取得进展，已收到原实控人冻结在案的款项。从执行程序启动到资金划转至上 市公司，全程历时不足一个月。 非经营性占用上市公司资金是严重损害上市公司利益和股东权益的违法行为。公告显示，2025年，经公 安机关侦办，检察院公诉和一审、二审法院审理，以背信损害上市公司利益罪判处生物谷原实控人、原 董秘兼财务总监二人有期徒刑并处罚金，判决将冻结在案的资金发还生物谷，并继续追缴违法所得退赔 生物谷。这不仅为挽回上市公司损失、保护投资者合法权益奠定了坚实基础，更有力维护了资本市场秩 序。 二审裁定生效后，执行法院快 ...

2026.02.06 沪深两市半日成交额1.38万亿，较上个交易日缩量633亿。市场逾3800股上涨。 11:11算力硬件股盘中持续回升，深南电路涨停，中富电路涨超10%，环旭电子、长光华芯、威尔高等 涨幅靠前。 作者 |一财阿驴 10:45名雕股份盘中上演"地天板"，成交近7亿元，走出6天5板，该股昨日盘中走出"天地板"。 11:31 A股午盘丨创业板指半日涨0.65% | | 分野 6日 1分 5分 15分 30分 60分 日 周 月 更多 F9 盘前盘后 桑加 九轮 面线 工具 @ 2 > | | | | | | --- | --- | --- | --- | --- | --- | | | 002830[名瞳版的] 10:45 份 30.65 游跌 2.79(10.01%) 均价 28.07 成交量 84 成交金额 24万 2026/02/06 | E 0-011 | | 30.65 +2.79 +10.019 | | | | | | | SZSE CNY 10:45:24 交割中 查看L2全餐 | | | 29.05 | | 7.51% | 曼比 | 100.00% 委统 | 123361 | | ...

2月6日，A股三大股指无惧外围暴跌压力，低开后迅速回升集体实现翻红，截至午盘，沪指上涨4.40 点，涨幅0.11%报4080.31点，深成指上涨90.46点，涨幅0.65%报14043.17点，创业板指上涨21.17点，涨 幅0.65%报3281.45点。沪深两市半日成交额1.38万亿，全市场超3800只个股上涨。 盘面热点快速轮动，化工（核心股）板块集体走强，沧州大化、金牛化工、百川股份、百合花涨停。人 形机器人（核心股）概念表现活跃，五洲新春、联诚精密、天奇股份涨停。有色金属（核心股）板块回 暖，湖南黄金、翔鹭钨业涨停。光通信概念震荡回升，杭电股份6天5板。中药概念开盘活跃，特一药业 涨停。下跌方面，大消费板块集体下挫，白酒、旅游酒店方向跌幅居前，皇台酒业跌停，大连圣亚触及 跌停。 多板块逆势上扬成市场亮点 中药（核心股）概念高开高走，盘龙药业、特一药业双双涨停，陇神戎发、生物谷、粤万年青高开超 12%，佛慈制药、新天药业等跟涨。 白酒（核心股）行业近期面临着一定的压力，一方面，春节前后的消费旺季已经过去，市场需求有所回 落；另一方面，行业竞争加剧，一些中小白酒企业为了抢占市场份额，采取了降价促销等手段， ...

早盘中药（核心股）板块逆势大涨，截至发稿振东制药大涨超19%，生物谷涨超13%，特一药业、汉森 制药涨停，恩威医药（核心股）、大唐药业涨超9%，粤万年青涨超8%，陇神戎发、奇正藏药、上海凯 宝涨超5%。 容，依托中药特色成分打造差异化产品，打开全新增长空间。 同时将梯度培育卓越企业，支持龙头设立产业发展基金、加大上市培育力度，还将推动中药（核心股） 大健康产品创新，打造"中药+"高附加值产业链，全方位促进中药行业规范化、现代化发展。 相关行业： 中药（核心股）材种植加工：方案提出建设高标准中药原料生产基地，鼓励发展中药材现代种业，提升 产地初加工自动化水平，推动制定中药材生产加工质量标准。相关种植加工企业将迎来标准化、规模化 发展机遇，道地药材生产企业将凭借产地属性优势进一步巩固市场地位，实现产品优质优价。 中药（核心股）创新研发：方案鼓励运用人工智能、大数据等技术赋能中药新药研发，推动经典名方、 医疗机构制剂转化为创新药，支持已上市中成药改良升级。布局中药创新研发、循证医学研究的企业将 受益于新药审批和市场推广支持，在创新产品涌现的行业趋势中抢占发展先机。 | | 名称 | 涨幅 | | --- | --- ...

Core Viewpoint - Lin Yanhe, the former chairman of Bio Valley, was sentenced to three years in prison for illegally transferring company funds to Shenzhen Jinsha River Investment Co., Ltd. The court rejected his request for probation [1][2]. Group 1: Legal Proceedings - Lin Yanhe was convicted of breaching trust and harming the interests of the listed company, receiving a three-year prison sentence and a fine of 5 million RMB. The former board secretary and financial director, He Yuan, was sentenced to 18 months in prison and fined 2 million RMB [2]. - The court ruled that the amount involved was particularly large and the social harm was severe, leading to the rejection of the defendants' requests for leniency based on self-reporting and contributions to damage control [2]. Group 2: Company Background - Bio Valley specializes in traditional Chinese medicine products, with its main products including Dan Zhan Sheng Mai capsules and Dan Zhan Xi Xin injections, which are used to treat ischemic cardiovascular and cerebrovascular diseases [2]. - The company transitioned from the New Third Board to the Beijing Stock Exchange in 2021 [2]. Group 3: Financial Misconduct Details - From August 2021 to March 2022, Lin Yanhe arranged for He Yuan to transfer a total of 277 million RMB in non-operating funds to Jinsha River Investment under the guise of entrusted financial management, with 122 million RMB in 2021 and 155 million RMB in early 2022 [4]. - As of July 19, 2022, only 20 million RMB of the occupied funds had been returned, leaving 257 million RMB outstanding [4]. Group 4: Regulatory Actions - Lin Yanhe faced investigation by the China Securities Regulatory Commission (CSRC) in May 2022 for information disclosure violations and was publicly reprimanded by the Beijing Stock Exchange in July 2022 for fund occupation [3]. - He resigned as chairman in July 2022 and was banned from the securities market for life in September 2022 [3].

Group 1 - Huaxia Happiness's board rejected five temporary proposals from major shareholder Ping An Life, with a voting result of 1 in favor and 7 against [1] - The proposals were intended for discussion at the third temporary shareholders' meeting of Huaxia Happiness in 2025 [1] Group 2 - Bio Valley announced that its former actual controller and chairman Lin Yanhe was sentenced to three years in prison and fined 5 million yuan for breaching trust and harming the company's interests [2][5] - The court also sentenced former board secretary and financial director He Yuan to one and a half years in prison and fined 200,000 yuan [2] Group 3 - The People's Bank of China announced a one-time credit repair policy to support individuals with damaged credit who are actively repaying debts [7] - Individuals who repay overdue debts of up to 10,000 yuan by March 31, 2026, will have their overdue information not displayed in the financial credit information database [7] Group 4 - The Shanghai Municipal Science and Technology Commission announced a plan to support the research and development of new food technologies, including alternative proteins and 3D-printed foods, from 2026 to 2030 [14] - The initiative aims to meet diverse food consumption needs and promote sustainable development [14] Group 5 - Xiangyu Medical reported that its brain-computer interface products have entered over 500 top-tier hospitals, with plans to expand to 700 by the Spring Festival and 1,500 by next year [24] - The company anticipates rapid growth in sales revenue from these products in 2026 [24] Group 6 - Geely Automobile announced the completion of the privatization and merger of Zeekr Intelligent Technology, making it a wholly-owned subsidiary [23] - Zeekr has been delisted from the New York Stock Exchange following the merger [23] Group 7 - China Nuclear Engineering announced that its subsidiaries will introduce 5 billion yuan in investment through a non-public agreement to implement market-oriented debt-to-equity swaps [32] - The funds will be used to repay financial institution loans while maintaining actual control over the subsidiaries [32]

Core Points - Yunnan Biotech Pharmaceutical Co., Ltd. (referred to as "Biotech") announced that the Yunnan Provincial High People's Court upheld the original ruling, sentencing former actual controller Lin Yanhe to three years in prison and a fine of 5 million yuan, while former CFO He Yuan received a sentence of one and a half years and a fine of 2 million yuan [1] - The case involved Lin Yanhe and He Yuan misappropriating company funds for personal financial needs, leading to administrative penalties from the China Securities Regulatory Commission (CSRC) and subsequent criminal charges [1][2] - The CSRC has been actively enforcing strict regulations against financial misconduct, emphasizing the protection of small investors and the integrity of innovative small and medium-sized enterprises [2] Company Overview - Biotech was established in 1999 and focuses on the research, production, and sales of traditional Chinese medicine, specifically the "Dengzhanhua" system [1] - The company transitioned from the New Third Board to the Beijing Stock Exchange in 2021 [1] Legal Proceedings - The case against Lin Yanhe and He Yuan for breaching fiduciary duties was heard in Kunming Intermediate People's Court, resulting in a conviction and financial penalties, with the court ordering the return of misappropriated funds to Biotech [2] - The Yunnan Securities Regulatory Bureau initiated an investigation into the misconduct, leading to significant administrative penalties and a referral for criminal prosecution [1][2]

Core Viewpoint - Yunnan Biological Valley Pharmaceutical Co., Ltd. has faced legal consequences for financial misconduct involving its former actual controller and financial director, highlighting the regulatory environment's strict stance against such violations [2][3]. Company Summary - Yunnan Biological Valley was established in 1999, focusing on the research, production, and sales of traditional Chinese medicine, specifically the "Dengzhanhua" system drugs. The company transitioned from the New Third Board to the Beijing Stock Exchange in 2021 [2]. - The former actual controller, Lin Yanhua, and the former financial director, He Yuan, were found guilty of misappropriating company funds for personal financial needs, leading to their convictions and sentences [2][3]. Regulatory Actions - In May 2022, the Yunnan Securities Regulatory Bureau initiated an investigation into the illegal activities, resulting in administrative penalties of 5 million yuan for Lin Yanhua and 2 million yuan for He Yuan, along with market entry bans [3]. - The case reflects the China Securities Regulatory Commission's commitment to combating financial misconduct and protecting the rights of small investors, emphasizing a zero-tolerance policy towards fund misappropriation [3].

生物谷（920266）12月3日大宗交易平台出现一笔成交，成交量10.00万股，成交金额70.00万元，大宗交 易成交价为7.00元，相对今日收盘价折价26.32%。该笔交易的买方营业部为中国银河证券股份有限公司 佛山绿景一路证券营业部，卖方营业部为国新证券股份有限公司昆明拓东路证券营业部。 据天眼查APP显示，云南生物谷药业股份有限公司成立于1999年06月13日，注册资本12400.0007万人民 币。（数据宝） 12月3日生物谷大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收 盘价折溢价 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | （%） | | | | | | | | 中国银河证券股份有限公 | 国新证券股份有限公 | | 10.00 | 70.00 | 7.00 | -26.32 | 司佛山绿景一路证券营业 | 司昆明拓东路证券营 | | | | | | 部 | 业部 | （文章来源：证券时报网） 进一步统计，近1个月内该股累计发生2笔大宗交易，合计成交金额为190.0 ...